Patents Assigned to Chinese PLA General Hospital
-
Publication number: 20230330146Abstract: Provided is a use of mesenchymal stem cells in the preparation of a drug for repairing lung damage caused by COVID-19. It is proved by clinical tests for the first time that mesenchymal stem cells have an excellent effect on repair of lung damage in subjects with viral pneumonia, especially severe pneumonia caused by SARS-CoV-2 infection, and can significantly reduce solid component lesion volume of the subjects, and repair lung tissue; moreover, it is proved by means of a six minute walking test that mesenchymal stem cells can significantly repair the subjects' cardiopulmonary function, so that the aerobic exercise capacity is significantly improved, thereby effectively alleviating sequelae of the subjects after the end of antiviral treatment, and improving health and quality of life of the subjects; in addition, mesenchymal stem cells are highly safe, and no obvious adverse reactions have been found.Type: ApplicationFiled: July 30, 2021Publication date: October 19, 2023Applicants: FIFTH MEDICAL CENTER OF CHINESE PLA GENERAL HOSPITAL, VCANBIO CELL & GENE ENGINEERING CORP., LTDInventors: Fusheng WANG, Lei SHI, Ruonan XU, Xin YUAN, Yu ZHANG, Weiqi YAO
-
Patent number: 11776120Abstract: A method for predicting the morphological changes of liver tumor after ablation based on deep learning includes: obtaining a medical image of liver tumor before ablation and a medical image of liver tumor after ablation; preprocessing the medical image of liver tumor before ablation and the medical image of liver tumor after ablation; obtaining a preoperative liver region map, postoperative liver region map, and postoperative liver tumor residual image map; obtaining a transformation matrix by a Coherent Point Drift (CPD) algorithm and obtaining a registration result map according to the transformation matrix; training the network by a random gradient descent method to obtain a liver tumor prediction model; using the liver tumor prediction model to predict the morphological changes of liver tumor after ablation. The method provides the basis for quantitatively evaluating whether the ablation area completely covers the tumor and facilitates the postoperative treatment plan for the patient.Type: GrantFiled: November 2, 2020Date of Patent: October 3, 2023Assignee: Chinese PLA General HospitalInventors: Ping Liang, Jie Yu, Linan Dong, Zhigang Cheng, Shouchao Wang, Xiaoling Yu, Fangyi Liu, Zhiyu Han
-
Patent number: 11753621Abstract: The invention discloses a method for constructing functional exosomes capable of efficiently loading specific miRNA. In order to enable the exosome to carry miRNA with specific regulation function more efficiently so as to play a role in targeted regulation more accurately and efficiently, MS2 phage capsid protein is utilized to edit and construct a capture element of a specific miRNA molecule, and placenta mesenchymal stem cells are reprogrammed to enable the secreted exosome to efficiently load a target miRNA molecule, so that the target miRNA molecule is delivered to tissue cells to play a role in effective regulation, and therefore a new strategy is provided for realizing specific precise treatment in the future.Type: GrantFiled: November 8, 2021Date of Patent: September 12, 2023Assignee: CHINESE PLA GENERAL HOSPITALInventors: Qiankun Li, Wenzhi Hu, Cuiping Zhang, Xiaobing Fu
-
Publication number: 20230168035Abstract: An energy-saving portable dryer for digestive endoscope is disclosed, including a box and a top cover. The box is a hollow shell structure, and the top cover covers the upper port of the box to form a sealed environment. The upper end of the top cover is provided with a controller to control the operation of the device. The box is internally provided with heating tubes. The box is provided with a water inlet and drainage mechanism. The bottom end of the box is provided with a liquid heater to heat the disinfection solution in the box to generate hot vapor. The top cover and the box are installed and disassembled through a fixed mechanism. The energy-saving portable dryer for digestive endoscope has the characteristics of energy saving and high efficiency. And its effect of disinfection and sterilization is better, which increases the practicability.Type: ApplicationFiled: January 17, 2023Publication date: June 1, 2023Applicant: The Second Medical Center?Chinese PLA General HospitalInventors: Ming WANG, Shiping XU, Hui SHI, Hailan ZHU
-
Publication number: 20230123842Abstract: A method for predicting the morphological changes of liver tumor after ablation based on deep learning includes: obtaining a medical image of liver tumor before ablation and a medical image of liver tumor after ablation; preprocessing the medical image of liver tumor before ablation and the medical image of liver tumor after ablation; obtaining a preoperative liver region map, postoperative liver region map, and postoperative liver tumor residual image map; obtaining a transformation matrix by a Coherent Point Drift (CPD) algorithm and obtaining a registration result map according to the transformation matrix; training the network by a random gradient descent method to obtain a liver tumor prediction model; using the liver tumor prediction model to predict the morphological changes of liver tumor after ablation. The method provides the basis for quantitatively evaluating whether the ablation area completely covers the tumor and facilitates the postoperative treatment plan for the patient.Type: ApplicationFiled: November 2, 2020Publication date: April 20, 2023Applicant: Chinese PLA General HospitalInventors: Ping LIANG, Jie YU, Linan DONG, Zhigang CHENG, Shouchao WANG, Xiaoling YU, Fangyi LIU, Zhiyu HAN
-
Patent number: 11628168Abstract: The present disclosure provides application of a compound in conformity with a general formula I and an isomer or pharmaceutically acceptable salt thereof to preparation of a medicinal composition for treating or preventing a high altitude disease. The high altitude disease is selected from an acute high altitude disease and a chronic high altitude disease generated in a high altitude environment with an altitude of 2,000 m or above.Type: GrantFiled: June 5, 2019Date of Patent: April 18, 2023Assignees: CHINESE PLA GENERAL HOSPITAL, SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT COMPANY, LTD.Inventors: Kunlun He, Xiaojian Gao, Chunlei Liu, Zeyu Zhang, Xin Li, Chen Li, Yunfu Luo, Maoyi Lei, Junmiao Li, Yiwei Wang
-
Patent number: 11534240Abstract: An intelligent monitoring system for pelvic fracture reduction, comprising a sample fracture model database, a patient pelvic fracture data acquisition unit, a reduction situation monitoring unit and a mixed reality data fusion processing unit, the sample fracture model database stores a plurality of sample fracture models, the patient pelvic fracture data acquisition unit uses magnetic navigation and positioning technology to collect patient pelvic location information data in real-time and upload it to the mixed reality data fusion processing unit, the mixed reality data fusion processing unit automatically invokes the sample fracture model in the sample fracture model database corresponding to patient pelvic fracture condition and matches the patient pelvic location information data with the sample fracture model using mixed reality technology to form an intelligent fracture model for the patient's pelvic fracture state, the reduction situation monitoring unit loads and displays images of the intelligent fType: GrantFiled: February 13, 2020Date of Patent: December 27, 2022Assignee: CHINESE PLA GENERAL HOSPITALInventors: Hua Chen, Peifu Tang
-
Publication number: 20220362359Abstract: Provided is use of a recombinant nucleic acid construct containing a B7-2-PE40 exotoxin fusion gene in the preparation of a DNA vaccine or medicament for treatment and/or prevention of type 1 diabetes. The DNA vaccine can reduce blood glucose in patient with type 1 diabetes, restore the secretion of insulin of the patients per se, and reduce the contents of islet cell autoantibody (ICA) and glutamate decarboxylase autoantibody (GAD) in the patients.Type: ApplicationFiled: March 2, 2020Publication date: November 17, 2022Applicant: The Fifth Medical Center of Chinese PLA General HospitalInventors: Yongzhi XI, Song YUN
-
Publication number: 20210393627Abstract: The present disclosure provides application of a compound in conformity with a general formula I and an isomer or pharmaceutically acceptable salt thereof to preparation of a medicinal composition for treating or preventing a high altitude disease. The high altitude disease is selected from an acute high altitude disease and a chronic high altitude disease generated in a high altitude environment with an altitude of 2,000 m or above.Type: ApplicationFiled: June 5, 2019Publication date: December 23, 2021Applicants: CHINESE PLA GENERAL HOSPITAL, SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT COMPANY, LTD.Inventors: Kunlun HE, Xiaojian GAO, Chunlei LIU, Zeyu ZHANG, Xin LI, Chen LI, Yunfu LUO, Maoyi LEI, Junmiao LI, Yiwei WANG
-
Publication number: 20210338665Abstract: The present disclosure provides application of a compound in conformity with a general formula I, and an isomer or pharmaceutically acceptable salt thereof to preparation of a medicinal composition for treating and/or preventing a high altitude disease. The high altitude disease is selected from an acute high altitude disease or a chronic high altitude disease generated in a high altitude environment with an altitude of 2,000 m or above.Type: ApplicationFiled: June 5, 2019Publication date: November 4, 2021Applicants: CHINESE PLA GENERAL HOSPITAL, SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT COMPANY, LTD.Inventors: Kunlun HE, Zeyu ZHANG, Xiaojian GAO, Chunlei LIU, Xin LI, Chen LI, Wenyuan QIAN, Chundao YANG, Guanghai XU, Yiwei WANG
-
Patent number: 9439881Abstract: The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.Type: GrantFiled: October 26, 2015Date of Patent: September 13, 2016Assignee: CHINESE PLA GENERAL HOSPITALInventors: Kunlun He, Song Li, Wu Zhong, Juan Liu, Lili Wang, Xin Li, Guoliang Hu, Jie Wang, Long Long, Junhai Xiao, Zhibing Zheng, Wei Li, Ruijun Li, Chunlei Liu, Jie Tang
-
Patent number: 9260384Abstract: A compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, is provided. Also, a composition containing a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents, is provided. Further, use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof for anti-apoptosis is provided, preventing or treating a disease or disorder associated with apoptosis; especially for protecting cardiomyocyte, preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.Type: GrantFiled: May 14, 2010Date of Patent: February 16, 2016Assignee: Chinese PLA General HospitalInventors: Kunlun He, Song Li, Wu Zhong, Juan Liu, Lili Wang, Xin Li, Guoliang Hu, Long Long, Junhai Xiao, Zhibing Zheng, Wei Li, Ruijun Li, Chunlei Liu, Jie Bai
-
Patent number: 9199978Abstract: The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.Type: GrantFiled: May 14, 2010Date of Patent: December 1, 2015Assignee: CHINESE PLA GENERAL HOSPITALInventors: Kunluu He, Song Li, Wu Zhong, Juan Liu, Lili Wang, Xin Li, Guoliang Hu, Jie Wang, Long Long, Junhai Xiao, Zhibing Zheng, Wei Li, Ruijun Li, Chunlei Liu, Jie Tang
-
Patent number: 8859587Abstract: The present invention relates to an acrylamide compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, to a composition comprising the compound or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluent, and to a use of the compound or the composition for prophylaxis and/or treatment of a disease or disorder associated with cardiomyocyte apoptosis.Type: GrantFiled: May 14, 2010Date of Patent: October 14, 2014Assignee: Chinese PLA General HospitalInventors: Kunlun He, Song Li, Lili Wang, Xin Li, Wu Zhong, Guoliang Hu, Jie Wang, Ruijin Li, Chunlei Liu, Junhai Xiao, Long Long, Wei Li, Hua Chen
-
Publication number: 20130158022Abstract: The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.Type: ApplicationFiled: May 14, 2010Publication date: June 20, 2013Applicant: CHINESE PLA GENERAL HOSPITALInventors: Kunlun He, Song Li, Wu Zhong, Juan Liu, Lili Wang, Xin Li, Guoliang Hu, Jie Wang, Long Long, Junhai Xiao, Zhibing Zheng, Wei Li, Ruijun Li, Chunlei Liu, Jie Tang
-
Publication number: 20130143917Abstract: The present invention relates to an acrylamide compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, to a composition comprising the compound or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluent, and to a use of the compound or the composition for prophylaxis and/or treatment of a disease or disorder associated with cardiomyocyte apoptosisType: ApplicationFiled: May 14, 2010Publication date: June 6, 2013Applicant: CHINESE PLA GENERAL HOSPITALInventors: Kunlun He, Song Li, Lili Wang, Xin Li, Wu Zhong, Guoliang Hu, Jie Wang, Ruijun Li, Chunlei Liu, Junhai Xiao, Long Long, Wei Li, Hua Chen
-
Publication number: 20130123300Abstract: A compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, is provided. Also, a composition containing a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents, is provided. Further, use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof for anti-apoptosis is provided, preventing or treating a disease or disorder associated with apoptosis; especially for protecting cardiomyocyte, preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.Type: ApplicationFiled: May 14, 2010Publication date: May 16, 2013Applicant: CHINESE PLA GENERAL HOSPITALInventors: Kunlun He, Song Li, Wu Zhong, Juan Liu, Lili Wang, Xin Li, Guoliang Hu, Long Long, Junhai Xiao, Zhibing Zheng, Wei Li, Ruijun Li, Chunlei Liu, Jie Bai
-
Patent number: 4870974Abstract: The apparatus and method of the present invention are used to detect the ECG and/or blood pressure (BP) waveforms and measure the R-R and Q-T intervals from the detected ECG signals, so as to determine the pulse structure of the heart stimulating signals, and to stimulate the heart. The heart is stimulated by the stimulating signals which includes a pacing pulse train applied to atrium for forming an artificial heart rhythm, and an inducing pulse train applied to ventricle for introducing ME or VT waveforms. By adjusting the time location and amplitude of the inducing pulses relative to the pacing pulses, the ME or VT waveforms are induced in the ECG signals. By detecting the ECG and/or BP waveforms, the ME or VT is identified and at the same time the heart stimulation is stopped. Then the induced ME or VT waveforms and the amplitude of the inducing pulse which induces the ME or VT waveforms are displayed and the ventricular fibrillation threshold is derived according to this amplitude.Type: GrantFiled: March 31, 1988Date of Patent: October 3, 1989Assignees: Chinese PLA General Hospital, CITIC Technology, Inc.Inventor: Xiangsheng Wang